4b05
From Proteopedia
(Difference between revisions)
m (Protected "4b05" [edit=sysop:move=sysop]) |
|||
| Line 1: | Line 1: | ||
'''Unreleased structure''' | '''Unreleased structure''' | ||
| - | The entry 4b05 is ON HOLD | + | The entry 4b05 is ON HOLD until Paper Publication |
Authors: Jeppsson, F., Eketjall, S., Janson, J., Karlstrom, S., Gustavsson, S., Olsson, L.L., Radesater, A., Ploeger, B., Cebers, G., Kolmodin, K., Swahn, B., vonBerg, S., Bueters, T., Falting, J. | Authors: Jeppsson, F., Eketjall, S., Janson, J., Karlstrom, S., Gustavsson, S., Olsson, L.L., Radesater, A., Ploeger, B., Cebers, G., Kolmodin, K., Swahn, B., vonBerg, S., Bueters, T., Falting, J. | ||
Description: Preclinical characterization of AZD3839, a novel clinical candidate BACE1 inhibitor for the treatment of Alzheimer Disease | Description: Preclinical characterization of AZD3839, a novel clinical candidate BACE1 inhibitor for the treatment of Alzheimer Disease | ||
Revision as of 07:41, 11 July 2012
Unreleased structure
The entry 4b05 is ON HOLD until Paper Publication
Authors: Jeppsson, F., Eketjall, S., Janson, J., Karlstrom, S., Gustavsson, S., Olsson, L.L., Radesater, A., Ploeger, B., Cebers, G., Kolmodin, K., Swahn, B., vonBerg, S., Bueters, T., Falting, J.
Description: Preclinical characterization of AZD3839, a novel clinical candidate BACE1 inhibitor for the treatment of Alzheimer Disease
